CYduct Diagnostics Statistics
CYduct Diagnostics (CYDX) Stock Statistics & Valuation Metrics
Total Valuation
CYduct Diagnostics has a market cap or net worth of $11.66M. The enterprise value is $2.81T.
- Market Cap
- $11.66M
- Enterprise Value
- $2.81T
Share Statistics
CYduct Diagnostics has 12,783,165 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,783,165
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
CYduct Diagnostics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 44.61%.
- Return on Equity (ROE)
- 0.20
- Return on Assets (ROA)
- -6.91
- Return on Invested Capital (ROIC)
- 44.61%
- Return on Capital Employed (ROCE)
- 0.36
- Revenue Per Employee
- 23.46K
- Profits Per Employee
- -69.13K
- Employee Count
- 3
- Asset Turnover
- 2.34
- Inventory Turnover
- 2.53
Valuation Ratios
The current PE Ratio of CYduct Diagnostics is -20.31. CYduct Diagnostics’s PEG ratio is -0.38.
- PE Ratio
- -20.31
- PS Ratio
- 165.63
- PB Ratio
- -11.05
- Price to FCF
- 1014.40
- Price to Operating Cash Flow
- 1013.96
- PEG Ratio
- -0.38
Income Statement
In the last 12 months, CYduct Diagnostics had revenue of 70.37K and earned -207.40K in profits. Earnings per share was -0.04.
- Revenue
- 70.37K
- Gross Profit
- 43.85K
- Operating Income
- -154.88K
- Pretax Income
- -207.40K
- Net Income
- -207.40K
- EBITDA
- -154.88K
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was 11.49K and capital expenditures -4, giving a free cash flow of 11.49K billion.
- Operating Cash Flow
- 11.49K
- Free Cash Flow
- 11.49K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
CYduct Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.10%
- Earnings Yield
- -1.78%
Stock Price Statistics
- Beta
- -1.05
- 52-Week Price Change
- 348.77%
- 50-Day Moving Average
- 0.66
- 200-Day Moving Average
- 0.90
- Relative Strength Index (RSI)
- 86.25
- Average Volume (3m)
- 2,157
Financial Position
CYduct Diagnostics as a current ratio of 0.07, with Debt / Equity ratio of -67.09%
- Current Ratio
- 0.07
- Quick Ratio
- 0.04
- Debt to Market Cap
- 0.30
- Net Debt to EBITDA
- -4.52
- Interest Coverage Ratio
- -2.95
Taxes
In the past 12 months, CYduct Diagnostics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CYduct Diagnostics EV to EBITDA ratio is -79.78, with an EV/FCF ratio of 1075.38.
- EV to Sales
- 175.59
- EV to EBITDA
- -79.78
- EV to Free Cash Flow
- 1075.38
- EV to Operating Cash Flow
- 1074.91
Balance Sheet
CYduct Diagnostics has $7,215.00 in cash and marketable securities with $707.90K in debt, giving a net cash position of -$700.68K billion.
- Cash & Marketable Securities
- $7,215.00
- Total Debt
- $707.90K
- Net Cash
- -$700.68K
- Net Cash Per Share
- -$0.05
- Tangible Book Value Per Share
- -$0.08
Margins
Gross margin is 62.32%, with operating margin of -220.10%, and net profit margin of -294.73%.
- Gross Margin
- 62.32%
- Operating Margin
- -220.10%
- Pretax Margin
- -294.73%
- Net Profit Margin
- -294.73%
- EBITDA Margin
- -220.10%
- EBIT Margin
- -220.10%
Analyst Forecast
The average price target for CYduct Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 13.36%
- EPS Growth Forecast
- 60.41%
